Guangdong Taienkang Pharmaceutical Co., Ltd. (hereinafter referred to as "Taienkang") was established in 1999 and is a new OTC market listed company (Stock Code: 831173). At present, the company has 8 wholly-owned subsidiaries, which form a regional operation network across 30 provinces of the country. To date, Taienkang’s marketing network and its sales team provide coverage to thousands of hospitals and 70,000 pharmacies in China and worldwide.
In the early days of Taienkang, the developmental route of pharmaceutical marketing was already determined. Taienkang is committed to selecting and marketing characteristic and competitive pharmaceutical products both in China and abroad. Ranging from market demand analysis, marketing strategy planning to product sales, channel developing and terminal management, customer relationship maintenance and other one-stop services, Taienkang has successfully obtained the agency operation of “Fishing Pill IV”，"Iodized Lecithin Tablets(Wolitine)", "Po Sum On Oil", "Levonorgestrel Pills (New Snow)” and other Johnson & Johnson medical devices. The self-produced “Wuhuan Brand” characteristic drugs for external use, exclusive patent variety “Fufang Wuji Wan”, “Tianfukang Brand” series of pills and “Taienkang Brand” medical consumables are well received on the market. During the Covid-19 pandemic in 2020, the disposable medical face masks produced by Taienkang not only assisted the control of the outbreak in China, but were also delivered to consumers from all over the world. In the same year, the domestic andrological drug Aitingjiu (Dapoxetine hydrochloride tablets) was R&D approved, which created a new category of andrological drugs. Taienkang has gradually established its core strengths in the field of pharmaceutical marketing.
Situated in the fierce competition within the economic environment of the pharmaceutical industry, Taienkang actively explores innovative business models and never cease increasing its production and R&D efforts. Through innovative production technology and improvement in the core technology of the product, Taienkang’s R&D center has determined its research and development strategy of seeing innovative drugs as the “top of the tower”, modified innovative drugs as the “body of the tower” and generic drugs as the “foundation of the tower”. Acting as a solid backing, research and development greatly enhance the core competitiveness of Taienkang. Taienkang fully implements the developmental theory of “work on one common thread, import inward and go global”; it also responds to the national strategy of “One Belt and One Road”. Through expanding the company’s business scope to the overseas market, exporting competitive Chinese products and importing competitive products from abroad, Taienkang maintains its original businesses advantages and marketing competitiveness.
In future, Taienkang will always adhere to its enterprise philosophy of "honesty, enterprise and sincerity”. The company sees public health as its own duty, innovation as its core development strategy. With a complete marketing network, products of excellent quality and a leading R&D team, Taienkang will enrich and improve its product system. Through industrializing a product technology platform and creating an efficient large-scale pharmaceutical production base, the company will enhance its core competitiveness within the market, promoting to construct a whole chain of "sales, production and research" as a comprehensive pharmaceutical enterprise. Taienkang aims to create a win-win cooperation with its partners, good values for the society, as well as making health products available to the customers. Taienkang will never stop bringing its own contribution to the social enterprise of public health.